Elixiron Immunotherapeutics (Cayman) Limited (TPEX:7871)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
68.10
-0.20 (-0.29%)
At close: May 28, 2026

TPEX:7871 Income Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023
Period Ending
Dec '25 Dec '24 Dec '23
50.290.825.7
Revenue Growth (YoY)
6162.39%-96.88%-
Cost of Revenue
0.30.642.21
Gross Profit
49.980.1723.48
Selling, General & Admin
58.5552.3541.42
Research & Development
187.99164.63103.01
Operating Expenses
246.53216.97144.43
Operating Income
-196.55-216.81-120.95
Interest Expense
-0.97-1.31-0.61
Interest & Investment Income
12.117.450.53
Earnings From Equity Investments
--0.31-
Currency Exchange Gain (Loss)
-2.411.92
Other Non Operating Income (Expenses)
-906.13-231.39391.07
EBT Excluding Unusual Items
-1,092-439.95271.95
Gain (Loss) on Sale of Assets
-0.02-
Other Unusual Items
--0.39-
Pretax Income
-1,092-440.32271.95
Income Tax Expense
14.97-3.74
Net Income
-1,107-440.32268.21
Net Income to Common
-1,107-440.32268.21
Shares Outstanding (Basic)
792222
Shares Outstanding (Diluted)
792280
Shares Change (YoY)
256.68%-72.30%-
EPS (Basic)
-14.02-19.9012.27
EPS (Diluted)
-14.02-19.903.36
Free Cash Flow
-132.48-249.67-105.55
Free Cash Flow Per Share
-1.68-11.28-1.32
Gross Margin
99.40%20.67%91.38%
Operating Margin
-390.85%-26999.63%-470.70%
Profit Margin
-2200.37%-54833.75%1043.79%
Free Cash Flow Margin
-263.44%-31091.78%-410.76%
EBITDA
-187.37-213.69-117.9
D&A For EBITDA
9.183.123.05
EBIT
-196.55-216.81-120.95
Effective Tax Rate
--1.38%